StudyGraphics #VisualAbstract Phase I: Adding carfilzomib to HyperCVAD in patients with newly diagnosed acute lymphoblastic leukemia showed favourable safety and efficacy outcomes February 19, 2021 | Kathleen Lau Facebook Twitter Pinterest WhatsApp Linkedin ReddIt Email Print RELATED ARTICLESMORE FROM AUTHOR #VisualAbstract Addition of daratumumab to standard of care improves minimal residual disease negativity in patients with newly diagnosed, transplant-ineligible multiple myeloma #VisualAbstract Menopausal hormone therapy was not associated with risk of cutaneous melanoma #VisualAbstract: Sentinel lymph node-guided neck dissection is noninferior to elective dissections for patients with early oral cavity squamous cell carcinoma
